Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Biophysical characterization of novel biomarkers and bioaffinity reagents (NanoMIPs): on the road for a low-cost diagnostic test for intestinal schistosomiasis

Created on 01 Aug 2026

Authors

Isopo, F., Stephen, A. N., Boumis, G., Giorgi, A., Eberini, I., Reddy, S. M., Miele, A. E.

Abstract

Schistosoma mansoni is a vector-borne intestinal parasite, endemic in ~70 tropical countries. Most of the World Health Organization interventions are based on mass drug administration (MDA) and sanitation. Since the parasite does not induce permanent immunity, reinfection rate is high, inducing scheduling of several MDA campaigns. To follow up after treatment and avoid blind MDA, providing a new rapid and cheap diagnostic test is needed, since the most used method is fifty years-old, lacks sensitivity and efficiency. Venom Allergen-Like proteins (SmVALs) have been previously identified as secreted/excreted proteins and potential biomarkers. Here we present the biophysical characterization of SmVAL11 and SmVAL13, their recognition by both specific antibodies and molecularly imprinted polymers (nanoMIPs), an easy-to-standardize alternative. The specific antibodies showed no cross-reactivity, while initial characterization of the nanoMIPs indicates a promising level of selectivity, establishing them as a reliable, cost-effective alternative. Therefore, our results are promising for the future development of a new cheap diagnostic test of intestinal schistosomiasis.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 01 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement